A Phase I, Randomized, Double-Blind (Sponsor Unblinded), Single-Center, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ascending Single and Repeat Intravenous Doses of GSK3342830 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Nov 2017
At a glance
- Drugs GSK 3342830 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 20 Nov 2017 Status changed from withdrawn prior to enrolment to discontinued.
- 14 Nov 2017 Planned End Date changed from 1 Nov 2017 to 2 Feb 2017.
- 14 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 2 Feb 2017.